Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HYZ2001
- Development stage
- Unknown
- Lead developer
- Tiandi Hengyi Pharmaceutical
- Administration
- Oral
01
Overview
**HYZ2001** is an investigational oral traditional Chinese medicine capsule being developed by Tiandi Hengyi Pharmaceutical for preventive treatment of migraine with the traditional Chinese medicine blood stasis obstructing collaterals pattern. It is being evaluated in a randomized, double-blind, placebo-controlled, multicenter Phase II study in China, with 12 weeks of treatment and efficacy assessments including changes in migraine days. Its constituent composition, molecular targets, and pharmacologic mechanism have not been publicly disclosed. ([pharnexcloud.com](https://www.pharnexcloud.com/data/lcsy_b4b0b6c0f9faf0d3e42fc8071755fc6f.html))
- Other names
- HYZ-2001HYZ2001HYZ 2001
Beyond the preview
Go deeper on HYZ2001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HYZ2001.